Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel DiseaseRemi Mahmoud, Bas Oldenburg, H. Schultheiss et al.|Clinical Gastroenterology and Hepatology|2022Cited by 31
Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry StudyMelek Simsek, Nanne K.H. de Boer, Ingrid Gisbertz et al.|Journal of Crohn s and Colitis|2023Cited by 12
P414 Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel DiseaseRemi Mahmoud, Bas Oldenburg, J Schultheiss et al.|Journal of Crohn s and Colitis|2021Cited by 3
P388 Prediction model to safely CEASE anti-TNF therapy in Crohn’s disease: validation of a predictive diagnostic tool for the cessation of anti-TNF treatment in CD in a Dutch populationSebastiaan ten Bokkel Huinink, Andrica de Vries, D. de Jong et al.|Journal of Crohn s and Colitis|2020Cited by 0
P309 Withdrawal of thiopurines in Inflammatory Bowel Disease patients in stable remission: a prospective, multicentre cohort studyEdo Savelkoul, Frank Hoentjen, Remi Mahmoud et al.|Journal of Crohn s and Colitis|2022Cited by 0